Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $15.45 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-11
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $14.06, a 10.02% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $12.78, a 50.79% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $25.97, a 99.92% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $12.99, a 642.29% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $13.45, a 50.09% decline from fiscal 2024.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $26.95, a 107.47% increase from fiscal 2023.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $12.99, a 15.48% decline from fiscal 2022.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $15.37, a 141.29% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.45 10-Q · filed 2026-08-11 | ||||||||
| 2026-03-31 | $14.06 10-Q · filed 2026-05-12 | ||||||||
| 2025-12-31 | $13.45 10-K · filed 2026-03-24 | ||||||||
| 2025-09-30 | $13.43 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | $13.18 10-Q · filed 2026-08-11 | ||||||||
| 2025-03-31 | $12.78 10-Q · filed 2026-05-12 | ||||||||
| 2024-12-31 | $26.95 10-K · filed 2026-03-24 | ||||||||
| 2024-09-30 | $26.52 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | $26.22 10-Q · filed 2025-08-11 | ||||||||
| 2024-03-31 | $25.97 10-Q · filed 2025-05-09 | ||||||||
| 2023-12-31 | $12.99 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | $12.99 10-Q · filed 2024-11-18 | $2.54 10-Q · filed 2023-11-14 | |||||||
| 2023-06-30 | $12.99 10-Q · filed 2024-08-09 | $0.51 10-Q · filed 2023-08-10 | |||||||
| 2023-03-31 | $12.99 10-Q · filed 2024-05-10 | $0.43 10-Q · filed 2023-05-08 | |||||||
| 2022-12-31 | $15.37 10-K · filed 2024-03-18 | $0.95 10-K · filed 2023-03-20 | |||||||
| 2022-09-30 | $4.80 10-Q · filed 2023-11-14 | $0.96 10-Q · filed 2022-11-14 | |||||||
| 2022-06-30 | $1.47 10-Q · filed 2023-08-10 | ||||||||
| 2022-03-31 | $1.75 10-Q · filed 2023-05-08 | ||||||||
| 2021-12-31 | $6.37 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | $6.49 10-Q · filed 2022-11-14 | ||||||||
| 2021-06-30 | $8.99 10-Q · filed 2022-08-09 | ||||||||
| 2021-03-31 | $9.43 10-Q · filed 2022-05-09 | ||||||||
| 2020-12-31 | $8.70 10-K · filed 2022-03-01 | ||||||||
| 2020-09-30 | $8.69 10-Q · filed 2021-11-04 | ||||||||
| 2020-06-30 | $7.84 10-Q · filed 2021-08-05 | ||||||||
| 2020-03-31 | $5.62 10-Q · filed 2021-05-12 | ||||||||
| 2019-12-31 | $2.17 10-K · filed 2021-03-25 | ||||||||
| 2019-09-30 | $2.63 10-Q · filed 2019-11-13 | $2.63 10-Q · filed 2019-11-13 | |||||||
| 2018-12-31 | $6.24 10-K · filed 2020-03-12 | ||||||||
| 2018-09-30 | $2.20 10-Q · filed 2019-11-13 | $6.25 10-Q · filed 2019-11-13 | |||||||
| 2018-06-30 | $9.60 10-Q · filed 2019-08-01 | $10.83 10-Q · filed 2019-08-01 | |||||||
| 2018-03-31 | $11.11 10-Q · filed 2019-05-07 | ||||||||
| 2017-12-31 | $11.85 10-K · filed 2020-03-12 | ||||||||
| 2017-09-30 | $11.13 10-Q · filed 2018-11-07 | $12.69 10-Q · filed 2018-11-07 | |||||||
| 2017-06-30 | $10.25 10-Q · filed 2018-08-08 | $12.72 10-Q · filed 2018-08-08 | |||||||
| 2017-03-31 | $13.02 10-Q · filed 2018-05-08 | ||||||||
| 2016-12-31 | $6.11 10-K · filed 2019-03-07 | ||||||||
| 2016-09-30 | $6.50 10-Q · filed 2017-11-08 | $5.76 10-Q · filed 2017-11-08 | |||||||
| 2016-06-30 | $5.27 10-Q · filed 2017-08-08 | $5.61 10-Q · filed 2017-08-08 | |||||||
| 2016-03-31 | $5.67 10-Q · filed 2017-05-09 | ||||||||
| 2015-12-31 | $8.91 10-K · filed 2018-03-12 | ||||||||
| 2015-09-30 | $9.02 10-Q · filed 2016-11-09 | ||||||||
| 2015-06-30 | $5.69 10-Q · filed 2016-08-04 | $9.02 10-Q · filed 2016-08-04 | |||||||
| 2015-03-31 | $9.21 10-Q · filed 2016-05-10 | ||||||||
| 2014-12-31 | $8.19 10-K · filed 2017-03-09 | ||||||||
| 2014-09-30 | $6.16 10-Q · filed 2015-11-10 | $8.33 10-Q · filed 2015-11-10 | |||||||
| 2014-06-30 | $8.30 10-Q · filed 2015-08-06 | $8.42 10-Q · filed 2015-08-06 | |||||||
| 2014-03-31 | $9.05 10-Q · filed 2015-05-12 | $4.23 10-Q · filed 2014-05-13 | |||||||
| 2013-12-31 | $0.40 10-K · filed 2016-03-14 | ||||||||
| 2013-09-30 | $2.92 10-Q · filed 2014-11-04 | ||||||||
| 2013-06-30 | $2.92 10-Q · filed 2014-08-11 | $2.92 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | $0.14 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |